Welcome to our dedicated page for NORD ANGLIA ED SEC filings (Ticker: NORD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Nordicus Partners Corporation (OTCQB: NORD) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand how Nordicus structures its capital-raising activities and records material corporate events related to its role as a business accelerator and holding company for Nordic and U.S. life sciences businesses.
Recent Form 8-K filings describe unregistered sales of equity securities to private investors. In these reports, Nordicus details private offerings of restricted common stock conducted under exemptions from registration provided by the Securities Act of 1933, including Section 4(a)(2), Regulation D, and Regulation S. The filings explain that the offerings did not involve general solicitation, that recipients were accredited investors or non-U.S. persons with access to information, and that the securities are subject to transfer restrictions and appropriate legends.
By reviewing Nordicus’ 8-K filings, users can see how the company raises capital to support its subsidiaries Orocidin A/S, Bio-Convert A/S, and NoviThera ApS, and how it documents material definitive agreements. These filings complement the company’s news releases about its application to uplist from the OTCQB Market to the Nasdaq Capital Market and its ongoing development programs in periodontitis, oral leukoplakia, and psoriasis.
On Stock Titan, Nordicus filings are updated as they are made available through EDGAR. AI-powered summaries highlight key terms of each transaction, such as the number of shares issued, offering prices, and the legal basis for registration exemptions, helping readers interpret complex legal language. Users can quickly identify items related to unregistered equity sales and other material events, and then drill into the full text of each filing for deeper analysis.
Nordicus Partners Corporation reported another pre-revenue quarter for the three months ended December 31, 2025, as it continues to build a portfolio of preclinical Nordic life sciences companies. Revenue was $0 compared with small related-party revenues in the prior year.
The company posted a net loss attributable to Nordicus of $1.23 million for the quarter and $3.95 million for the nine months, driven mainly by officer compensation, professional fees, and $1.32 million in research and development expenses over nine months. Comprehensive income for the nine months was positive $0.92 million, helped by $4.88 million in foreign currency translation gains.
At December 31, 2025, Nordicus held $189,297 in cash and total assets of $75.9 million, largely in goodwill and in-process R&D from acquisitions of Orocidin and Bio-Convert. Accumulated deficit reached $50.7 million, and management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing.
During the nine months, Nordicus raised about $3.9 million through private issuances of 1.69 million restricted shares, and subsequently raised $1.5 million from 547,036 shares at $2.75 per share. It also repurchased 57,642 shares under a limited buyback program. The portfolio now includes majority stakes in Orocidin, Bio-Convert and NoviThera, all targeting oral health and dermatology indications in preclinical stages.
Nordicus Partners Corporation reports that on November 10, 2025, its board of directors created three standing committees and adopted formal charters for each. The new committees are the Audit Committee, Compensation Committee and Nominating Committee.
The Audit Committee is composed of Kim Mücke (chair), Andrew J. Ritter and Peter Severin, and the board has designated Mr. Mücke as an “audit committee financial expert” under Securities and Exchange Commission rules. The Compensation Committee and Nominating Committee each consist of the same three directors, with different directors serving as chairs. The detailed charters for these committees are filed as exhibits to this report.
Nordicus Partners Corporation reported that in December 2025 it issued a total of 131,000 restricted shares of its common stock to ten private investors at a price of $2.75 per share. On January 5, 2026, the company decided to close this private offering on those terms. The shares were issued in a private placement and have not been registered under U.S. or other applicable securities laws, so they are subject to transfer restrictions and can only be resold under an effective registration statement or a valid exemption.
The company states that it is relying on exemptions from registration under Section 4(a)(2) of the Securities Act, Rule 506(b) and (c) of Regulation D, and Regulation S. The investors were accredited and/or had access to detailed information, there was no general solicitation, no underwriters or agents were involved, and no underwriting discounts or commissions were paid.
Nordicus Partners Corporation reported that from October through December 2025 it issued 416,000 restricted shares of its common stock in a private offering to eight investors at a price of $2.75 per share, and on December 5, 2025 determined to close the offering on these terms. The shares were sold without registration under the Securities Act of 1933, relying on exemptions including Section 4(a)(2), Rule 506(b) and (c) of Regulation D, and Regulation S. Investors were accredited and/or had access to information similar to a registration statement, acquired the stock for investment purposes, and the securities carry transfer restrictions and restrictive legends. No underwriters or agents participated, no underwriting discounts or commissions were paid, and there was no general solicitation.
Nordicus Partners Corporation (NORD) reported Q2 FY2026 results for the quarter ended September 30, 2025. The company recorded no revenue and a net loss of $1,511,474, or $0.08 per share. Operating expenses were $1,211,478, driven by officer compensation, R&D, and G&A. For the first six months, net loss totaled $2,718,360.
Liquidity remains tight. Cash was $242,155 as of September 30, 2025, after net cash used in operations of $2,188,401 in the six-month period. Financing cash inflows of $2,419,220 came from issuing 1,146,500 common shares. The company disclosed a going concern uncertainty due to nominal revenue, accumulated deficit of $49,503,208, and limited cash. Subsequent to quarter-end, it raised $618,750 via 225,000 restricted shares at $2.75 and repurchased 57,642 shares at $1.36.
Total assets were $75,882,821, including in-process R&D of $46,402,880 and goodwill of $27,696,030 tied to Orocidin A/S and Bio-Convert A/S. A fair-value decrease of $675,000 was recorded on the Mag Mile Capital investment over six months. Shares outstanding were 18,399,002 at quarter-end and 18,566,360 as of November 12, 2025.
Nordicus Partners (NORD) filed a Form 4 showing CEO Henrik Rouf sold company stock across four dates and updated his holdings. Reported sales were: 2,500 shares at $6 on 11/15/2024; 10,000 shares at $5 on 01/03/2025; 3,362 shares at $4.16 on 01/13/2025; and 26,667 shares at $2 on 08/20/2025.
Following these transactions, Mr. Rouf beneficially owns 15,973 shares. The filing notes a 1-for-10 reverse stock split effected on November 8, 2024. Of the 15,973 shares, 640 shares are held personally and 15,333 shares are held in the name of Reddington Partners LLC, for which Mr. Rouf is the sole beneficial owner.
Nordicus Partners Corp (NORD): Form 4 insider activity — A reporting person filed transactions spanning 12/19/2024 to 08/08/2025. Activity included conversions, open‑market buys and sells, and gifts. Notable entries: a conversion adding 10,000 shares at $10 on 12/19/2024; a purchase of 11,528 shares at $4 and sales of 54,223 and 7,500 shares at $4 and $3 on 02/03/2025; a conversion adding 11,224 shares at $8.91 on 02/13/2025; multiple purchases at $5 in May 2025; and a sale of 23,300 shares at $2 on 08/08/2025. Following the last reported transaction, beneficial ownership stood at 3,259,025 shares, held directly.
The filing notes gifts on 05/28/2025, including a gift from an affiliate shareholder, AC Nordic ApS, and private gift transfers.
Nordicus Partners Corp (NORD) Form 4: AC Nordic ApS, a reporting person and director, reported multiple purchases, sales and gifts of common stock between 02/18/2025 and 07/30/2025. The filing shows purchases: 2,000 shares at $5.00 (02/18/2025), 1,982 shares at $8.85 (06/02/2025), 35,000 shares at $4.00 (06/16/2025), 25,000 shares at $1.90 (07/02/2025), 42,500 shares at $1.90 (07/03/2025) and 100,000 shares at $1.90 (07/30/2025), plus a 109,750-share gift (05/28/2025) and a 113,095-share gift to GK Partners ApS (05/28/2025). Sales reported: 4,000 and 3,500 shares on 02/18/2025 at $1.90. Following the transactions the reporting person beneficially owned 3,119,335 shares. The form states transactions were reported late due to an inadvertent administrative error and is signed by the CEO.
AC Nordic ApS reports beneficial ownership of 3,119,335 shares of Nordicus Partners Corp common stock, representing 17.42% of 17,901,551 outstanding shares. The filing lists multiple private acquisitions between February and July 2025 at purchase prices ranging from $1.90 to $8.85 per share, purchases from the issuer on specific dates, and two gifts on May 28, 2025 totaling 222,845 shares (109,750 and 113,095). The reporting person, organized in Denmark and controlled by Torben Steen Jensen, states the transactions serve a long-term strategy of asset diversification and liquidity and disclaims any current plans to pursue corporate control, board changes, restructurings, or other material actions.
Nordicus Partners Corporation entered into a material definitive agreement involving a private sale of its common stock. From July through September 2025, the company issued a total of 1,057,500 restricted shares of common stock at a price of $1.90 per share to 54 private investors, and on September 18, 2025 it decided to close this private offering on those terms.
The shares were issued as unregistered securities under the Securities Act of 1933, relying on exemptions including Section 4(a)(2), Rule 506(b) and (c) of Regulation D, and Regulation S for non-U.S. persons. Investors were accredited and/or received information similar to a registration statement, purchased for investment purposes, and the offering involved no general solicitation, underwriters, or commissions. The securities carry transfer restrictions and are subject to restrictive legends reflecting their unregistered status.